ReVance Therapeutics Obtains $5,000,000 New Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0586ad90-8d0d-443a-bb84-bd366a69dc4d&Preview=1
Date
2/3/2011
Company Name
ReVance Therapeutics
Mailing Address
7555 Gateway Boulevard Newark, CA 94560
Company Description
Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis.
Website
http://www.revance.com
Transaction Type
Venture Equity
Transaction Amount
$5,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing.
M&A Terms
Venture Investor
Undisclosed